Bluefish Pharmaceuticals

Stockholm, Sweden Founded: 2005 • Age: 21 yrs
Bioequivalent generic pharmaceuticals are developed and manufactured affordably.

About Bluefish Pharmaceuticals

Bluefish Pharmaceuticals is a Healthcare company based in Stockholm (Sweden) founded in 2005. Bioequivalent generic pharmaceuticals are developed and manufactured affordably. Bluefish Pharmaceuticals has raised $21.67 million across 5 funding rounds from investors including Catella, NXT2B and Varenne. The company has 81 employees. Its Indian entity Bluefish Pharmaceuticals Private Limited reported revenue of β‚Ή24.17 Cr. Bluefish Pharmaceuticals offers products and services including Generic Medicines and Partnering Services. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Manufacturer of affordable generic pharmaceutical products. It focuses on developing and marketing bioequivalent versions of off-patent medications. The company partners with manufacturing experts to ensure rigorous quality standards are met throughout the product lifecycle, from development to distribution. Its marketing strategy emphasizes organic growth and market-specific approaches, targeting various healthcare institutions. The products are derived from well-established generic substances, with extensive research supporting their efficacy and safety. This approach minimizes development time and optimizes investments, resulting in a cost-effective product portfolio.

Key Metrics
  • Indian entity revenue
    ₹24.17 Cr

    FY 2025 · -2% YoY

  • Indian entity net profit
    ₹1.76 Cr

    FY 2025 · 7% margin

  • Indian entity EBITDA
    ₹2.85 Cr

    FY 2025 · 12% margin

  • Total Equity Funding
    $21.67M (USD)

    in 5 rounds

  • Latest Funding Round
    $3.3M (USD), Series B

    May 2014

  • Investors
    Catella

    & 2 more

  • Employee Count
    81

Products & Services of Bluefish Pharmaceuticals

Bluefish Pharmaceuticals offers a comprehensive portfolio of products and services, including Generic Medicines and Partnering Services.

Generic Medicines
Pharmaceutical Products

Generic medicines are manufactured for various therapeutic areas, with bioequivalence established to originator products to ensure affordability and efficacy.

Partnering Services
Business Services

Partnerships are provided with development and manufacturing experts to optimize product portfolios and supply chains in the pharmaceutical sector.

Funding Insights of Bluefish Pharmaceuticals

Bluefish Pharmaceuticals has successfully raised a total of $21.67M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $3.3 million completed in May 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $21.67M
  • Total Rounds 5
  • Last Round Series B β€” $3.3M
  • Investors Count 3

All 5 funding rounds of Bluefish Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2014$3.3MSeries B––
–
Dec 2011$5.93MSeries B––
May 2011$9.6MSeries B––
–
Jun 2007$2.83MSeries A––
Jun 2006Seed––
Valuation history

3 investors in total: 3 institutional.

Investors in Bluefish Pharmaceuticals

Bluefish Pharmaceuticals has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Catella, NXT2B and Varenne.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
NXT2B is recognized as a venture capital investment firm.
2011nxt2b.comUppsala, Sweden
Companies are supported by Varenne in their growth journey.
varenne.seStockholm, Sweden
M&A strategic advisory and real estate services are provided globally.
1987catella.comStockholm, Sweden
Premium access

Investor details for Bluefish Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Bluefish Pharmaceuticals Private Limited (Bluefish Pharmaceuticals)

Bluefish Pharmaceuticals Private Limited is the primary company behind Bluefish Pharmaceuticals. The board of Bluefish Pharmaceuticals Private Limited currently have 2 directors; the longest-serving is Vivekanandan Sundaramurthy, appointed in 2021. 13 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Vivekanandan Sundaramurthy
DIN 09289475
Director23 Aug 20215 yrs 2 moBluefish Pharmaceuticals Private Limited
Astha Sehgal
DIN 09404915
Director19 Nov 20214 yrs 11 moBluefish Pharmaceuticals Private Limited

People of Bluefish Pharmaceuticals

14 people are tracked at Bluefish Pharmaceuticals (7 in leadership, 7 in team); the tracked headcount is 81.

NameRoleGroup
Fredrik Sehlstedt
Chief Financial OfficerLeadership
Head – Human ResourcesLeadership
Ingrid Smerdova
Director Business DevelopmentLeadership
Vivekanand Sundaramurthy
Head – Research & DevelopmentLeadership
Paul Lister
Head Of Supply ChainLeadership
Yogesh Kota
Director Operation And Head Of Supplier Relations- SCMLeadership
Sunil Bolar
Director Of Business DevelopmentLeadership
Eden Kebede
Manager-business DevelopmentTeam
Savinay Gokavi
Manager- TT & Launch ManagerTeam
Louise Danielsson
Sales ManagerTeam
Wojciech Stras
Country ManagerTeam
Belén Hernández López
Finance, Operations & Customer ServiceTeam
Ana Aguado González
Sales LeadTeam
Kenneth Edman
Interim Senior AccountantTeam
Premium access

Complete people profiles for Bluefish Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Bluefish Pharmaceuticals

Figures of Bluefish Pharmaceuticals Private Limited, the primary company behind Bluefish Pharmaceuticals, for FY 2025. Revenue was ₹24.17 Cr (-2% year on year). Net profit was ₹1.76 Cr (7% margin). EBITDA was ₹2.85 Cr (12% margin). Revenue has grown at a compounded annual rate of +5% over three years and +4% over five years.

  • ₹24.17 CrRevenue · FY 2025 · -2% YoY
  • ₹1.76 CrNet profit · 7% margin
  • ₹2.85 CrEBITDA · 12% margin
  • ₹2.40 CrPaid-up capital
  • 81Employees (provident fund records)
  • +5%Revenue CAGR, 3 years
  • +4%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Bluefish Pharmaceuticals Private Limited are on its company page.

Premium access

Detailed financial statements for Bluefish Pharmaceuticals

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Bluefish Pharmaceuticals

3 dated milestones of Bluefish Pharmaceuticals across 9 years, from founding to its latest funding, stage changes and deals.

  1. Founded Bluefish Pharmaceuticals is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Series B, of $3.3M.

Web traffic of Bluefish Pharmaceuticals

The website of Bluefish Pharmaceuticals (bluefishpharma.com) receives about 2.3K visits a month.

  • Monthly visits
    2.3K

    ▲ 0.6% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Bluefish Pharmaceuticals

Bluefish Pharmaceuticals was founded in 2005 and raised its 1st funding round 1 year after it was founded.

Bluefish Pharmaceuticals is headquartered in Stockholm, Sweden.

Bluefish Pharmaceuticals is a funded company, having raised a total of $21.67M across 5 funding rounds to date.

Bluefish Pharmaceuticals has 81 employees.

The primary company behind Bluefish Pharmaceuticals, Bluefish Pharmaceuticals Private Limited, reported revenue of β‚Ή24.17 Cr for FY 2025, down 2% year on year.

Manufacturer of affordable generic pharmaceutical products. It focuses on developing and marketing bioequivalent versions of off-patent medications. The company partners with manufacturing experts to ensure rigorous quality standards are met throughout the product lifecycle, from development to distribution. Its marketing strategy emphasizes organic growth and market-specific approaches, targeting various healthcare institutions. The products are derived from well-established generic substances, with extensive research supporting their efficacy and safety. This approach minimizes development time and optimizes investments, resulting in a cost-effective product portfolio.

Bluefish Pharmaceuticals offers Generic Medicines and Partnering Services.

Bluefish Pharmaceuticals has 3 investors. Key investors include Catella, NXT2B, and Varenne.

Bluefish Pharmaceuticals operates through Bluefish Pharmaceuticals Private Limited.

The legal entities of Bluefish Pharmaceuticals currently have 2 directors, including Vivekanandan Sundaramurthy, Astha Sehgal.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available